- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05482737
Clinical Impact of Red Cell Storage Age
October 2, 2024 updated by: University of Minnesota
Clinical Impact of Red Cell Storage Age: Individual Patient Data Meta-Analysis of Four Recent Large Randomized Trials
The recent four RCTs evaluating effects of RBC storage age on morbidity and mortality found no statistically significant adverse effects of longer stored RBC compared to shorter storage ages.
Unfortunately, none of these RCTs had sufficient numbers of subjects receiving RBC at either storage age extreme to identify consequences of RBC transfusion at these limits.
To better investigate effects of RBC storage age on clinical outcomes, this study will perform secondary meta-analyses of merged common patient data elements -individual patient data (IPD) meta-analysis (IPDMA) - from the nearly 33,000 subjects enrolled in the four RCTs.
Study Overview
Study Type
Observational
Enrollment (Actual)
33000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Subjects in the recent four RCTs who are 18 years or older and have received at least one RBC transfusion.
Description
Inclusion Criteria:
- Received at least one RBC transfusion
- >=18 years of age
Exclusion Criteria:
- N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Reference group
Transfused RBC stored 8-35 days
|
This is an observational retrospective study (meta-analysis)
|
|
less than or equal 7 days
Transfused RBC stored =<7 days
|
This is an observational retrospective study (meta-analysis)
|
|
more than 7 days
Transfused RBC stored <7 days
|
This is an observational retrospective study (meta-analysis)
|
|
less that or equal 10 days
Transfused RBC stored =<10 days
|
This is an observational retrospective study (meta-analysis)
|
|
more that 10 days
Transfused RBC stored >10 days
|
This is an observational retrospective study (meta-analysis)
|
|
more than 35 days
Transfused RBC stored >35 days
|
This is an observational retrospective study (meta-analysis)
|
|
less than or equal 35 days
Transfused RBC stored =<35 days
|
This is an observational retrospective study (meta-analysis)
|
|
less than 18 days
Transfused RBC stored <18 days
|
This is an observational retrospective study (meta-analysis)
|
|
more than or equal 18 days
Transfused RBC stored =>18 days
|
This is an observational retrospective study (meta-analysis)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality
Time Frame: 28 days after transfusion
|
Estimate the effect of transfused RBC storage-age on time to all-cause mortality
|
28 days after transfusion
|
|
Hospital length of stay
Time Frame: after transfusion through 28 days
|
Estimate the effect of transfused RBC storage-age on hospital stay
|
after transfusion through 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality at 28 days for long-storage
Time Frame: 28 days after transfusion
|
all-cause mortality at 28 days comparing subjects who received (one or more) RBC unit ≥ 35 days vs. no unit > 35 days
|
28 days after transfusion
|
|
28 day mortality for short-storage
Time Frame: 28 days after transfusion
|
28 day mortality for subjects who received (one or more) RBC unit ≤ 7 days vs. no unit ≤ 7 days
|
28 days after transfusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marie Steiner, MD, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2019
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
August 30, 2024
Study Registration Dates
First Submitted
July 27, 2022
First Submitted That Met QC Criteria
July 28, 2022
First Posted (Actual)
August 1, 2022
Study Record Updates
Last Update Posted (Actual)
October 3, 2024
Last Update Submitted That Met QC Criteria
October 2, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Pending 4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.